Lipocine(US:LPCN)2026-03-10 01:09Financial Performance - Total revenues for 2025 were $1,976,677, a decrease of 82.3% compared to $11,198,144 in 2024[404] - License revenue dropped to $1,500,000 in 2025 from $10,900,000 in 2024, reflecting a decline of 86.2%[404] - The operating loss for 2025 was $10,371,379, compared to an operating loss of $1,155,035 in 2024[404] - Net loss for 2025 was $9,627,505, contrasting with a net income of $8,352 in 2024[404] - Total revenue for 2025 was $1.98 million, a decrease of 82.4% from $11.20 million in 2024[417] - The company reported a net loss of $9.63 million for the year ended December 31, 2025, compared to a net income of $8,352 in 2024[407] - The Company reported a net loss of $9,627,505 for the year ended December 31, 2025, compared to a net income of $8,352 in 2024[449] - The net loss for the year ended December 31, 2025, was $9,627,505, compared to a net income of $8,352 in 2024[519] Cash and Assets - Cash and cash equivalents decreased to $5,205,842 as of December 31, 2025, down from $6,205,926 in 2024, a decline of 16.1%[402] - Total assets fell to $17,005,612 in 2025 from $22,510,501 in 2024, a decrease of 24.5%[402] - Total stockholders' equity decreased to $14,477,416 in 2025 from $20,997,565 in 2024, a decline of 30.9%[402] - Cash and cash equivalents at the end of 2025 were $5.21 million, down from $6.21 million at the end of 2024[411] - The Company had cash, cash equivalents, and marketable securities of approximately $14.9 million as of December 31, 2025[454] - The fair value of cash equivalents and government treasury bills was $14,184,232 as of December 31, 2025, down from $21,582,552 in 2024[441] Expenses - Research and development expenses increased to $8,583,919 in 2025, up from $7,351,753 in 2024, representing a rise of 16.7%[404] - Cash used in operating activities was $9.76 million in 2025, significantly higher than $1.22 million in 2024[407] - The Company incurred approximately $5.1 million in research and development expenses in 2025, up from $4.1 million in 2024[469] - Personnel costs increased to $4,031,626 in 2025 from $3,536,529 in 2024[519] - The Company’s rent expense was $376,000 for the year ended December 31, 2025, compared to $366,000 in 2024, reflecting a 3.7% increase[485] Stock and Equity - The company raised $2.87 million through the sale of common stock via an ATM offering in 2025, compared to $209,340 in 2024[407] - The Company issued 100,994 stock options in 2025 compared to 84,715 in 2024, and issued 0 restricted stock units in 2025 compared to 21,762 in 2024[431] - As of December 31, 2025, the Company has 417,309 outstanding stock options with a weighted average exercise price of $18.64 and a remaining contractual life of 6.70 years[505] - The Company has registered up to $50,000,000 of common shares for sale under the A.G.P. Sales Agreement, allowing for "at the market" offerings[493] - The Company has reduced the number of authorized shares of common stock from 200,000,000 to 75,000,000 as of June 4, 2025[489] - The Company’s stockholders approved an amendment to reduce the number of authorized shares, which became effective upon filing with the Secretary of State[489] - The Company’s stockholders approved a Rights Agreement that allows for the purchase of preferred stock under certain conditions, enhancing shareholder protection[498] Clinical and Product Development - The company has ongoing and planned clinical trials, with expectations for future product candidates and regulatory approvals[16] - The Company recognized 74.7% of its revenue from the Verity License agreement in 2025, amounting to $1.50 million[421] - The Company entered into the Verity License Agreement, granting GSL exclusive rights to commercialize TLANDO, with an initial license fee of $11.0 million, including payments of $2.5 million, $5.0 million, $2.5 million, and $1.0 million due by January 2026[458] - The Company recognized $1.0 million in licensing revenue and approximately $477,000 in sales-based royalty revenue under the Verity License Agreement during 2025[462] - The Company is eligible for development and sales milestone payments of up to $259.0 million based on sales achievements under the Verity License Agreement[459] - The Company entered into a Distribution and License Agreement with SPC Korea, receiving a one-time upfront fee and additional payments for marketing milestones, along with royalties on net sales in South Korea[463] - The Company has agreements with Pharmalink and Aché for TLANDO distribution in the GCC and Brazil, respectively, with both agreements including upfront fees and milestone payments[464][465] Tax and Deferred Assets - The income tax expense for 2025 was $200, a decrease from $681 in 2024, primarily due to changes in valuation allowance[474][475] - As of December 31, 2025, the Company had net deferred tax assets of $51.0 million, with a valuation allowance of the same amount, indicating uncertainty in realizing these benefits[477] - The Company has approximately $160.8 million in net operating loss carryforwards, with $46.5 million set to expire between 2025 and 2035[481] Miscellaneous - The Company operates as a single reporting segment focused on leveraging its proprietary drug delivery technology platform[517] - The common stock warrants from the February 2020 offering, which expired in February 2025, were classified as equity and no warrants were exercised during 2025[509] - The aggregate intrinsic value of outstanding stock options as of December 31, 2025, was $278,000, compared to approximately $29,000 as of December 31, 2024[507] - The company contributed $104,000 and $109,000 to the 401(k) Plan during the years ended December 31, 2025, and 2024, respectively[512] - The company sold 1,138,710 shares of common stock for net proceeds of $10.6 million under the A.G.P. Sales Agreement since December 31, 2025[526]